/ Print /

AMCP 2017

Shifting trends in the pharmaceutical marketplace: What to watchFrom public furor over price hikes to the loss of patent protections for blockbuster drugs, big changes are afoot in the pharmaceutical marketplace. Read more.
Incremental clinical advances for Duchenne Muscular DystrophyJust last year, the FDA approved Exondys 51 (eteplirsen) for DMD, over the recommendations of FDA scientists and an external scientific advisory committee. Read more.
Rapid oncology innovation raises management challenges for payersOncology is a complex and rapidly-evolving management challenge for payers.
Top challenges likely to slow adoption of biosimilarsBiosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.
The Health Economics of Medical Pot and the Pharmacist’s Role
The Health Economics of Medical Pot and the Pharmacist’s RoleEven medical marijuana has health-care costs and outcomes.
Top considerations when determining whether to approve expensive drugsWeighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.
Expedited FDA approval plays dominant role in drug approvalsLast year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017.
Predictive analytics reduces chemotherapy-associated hospitalizationsPatient risk can improve value-based cancer care. Find out how.
What to do About Rising Health-Care Costs?
What to do About Rising Health-Care Costs?Taking a clear-eyed look at the cost of health care can reduce waste.
What’s in the Specialty Pharmacy Pipeline?
What’s in the Specialty Pharmacy Pipeline?Biosimilars, cancer drugs, and orphan drugs are heading towards FDA approval in 2017.